Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Plume chief medical officer Jerrica Kirkley (left). Photos: Plume

Transgender health needs, long neglected by the medical establishment, could get a needed assist from tech, as a pair of startups that focus on hormone treatment and other services today announce fresh venture funding.

Why it matters: Transgender and non-binary people can face enormous barriers to health care, from a scarcity of facilities that provide gender-affirming care to insurance company denials and outright discrimination.

  • Today's announcements are also noteworthy as few companies focused on LGBT consumers — and transgender people in particular — have attracted venture funding.

Driving the news: Plume and Folx are both announcing Series A funding rounds today.

  • Both firms bypass traditional insurance and provide needed care online, directly to consumers.
  • Plume is more narrowly targeted at transgender-specific care, while Folx offers services for the broader LGBTQ community.

Details: Plume charges $99 per month for a service that includes online doctor visits and lab work, as well as referral letters people may need in order to get gender-affirming surgery or legally change their name or gender.

  • Folx charges $59 per month, which covers doctor visits, lab work and the least expensive hormone medications. (Injectable medications, including supplies, cost extra.)
  • Folx plans to offer additional services addressing other queer health needs, including STI testing. It is initially available in 11 states, with an aim to expand nationwide.

By the numbers: Plume is announcing $14 million in Series A funding Craft Ventures with participation from General Catalyst, Slow Ventures and Town Hall Ventures.

  • Folx has attracted $25 million in Series A investment, led by Bessemer Venture Partners.

The big picture: Folx and Plume are part of a broader trend of direct-to-consumer startups that offer health services that are hard to find, aren't covered by insurance or have a history of being poorly served by the medical establishment.

  • The heads of both companies said they encountered some skepticism from potential investors, but were able to show both a huge unmet need in the existing market and a population that is growing in size and economic power.
  • Also important, Folx CEO A.G. Breitenstein said, is the fact that more venture firms now have queer and trans people on staff.

Between the lines: Affirming care that people can access from their homes has benefits in big cities where people might wait weeks for an appointment at a trans or queer health clinic.

  • But it's even more useful for those in rural areas that may not have any nearby options for trans- and queer-affirming health care.

What they're saying: "Access to gender-affirming care can be lifesaving for those who need it," said Lainy Painter, a principal at Plume investor Craft Ventures. "While a small number of clinics have focused on the trans community, the vast majority of patients have been unable to access affordable care."

  • Jerrica Kirkley, Plume's chief medical officer, said she has seen the failings of the system both as a patient seeking trans-specific health care and as a doctor. "I knew there had to be a better way," she said.

Yes, but: There are plenty of trans people who can't afford the monthly fees for Plume or Folx. Both companies are working on grant programs to help some people that couldn't otherwise access their services.

What's next: Fresh growth opportunities for the companies include mental health services, general health care and prosthetics, as well as services for transgender youth.

  • Folx has also said it wants to expand into family creation services.

Go deeper

Cuomo barraged by fellow Dems after second harassment accusation

New York Gov. Andrew Cuomo faced a barrage of criticism from fellow Democrats after The New York Times reported that the second former aide in four days had accused him of sexual harassment.

Why it matters: Cuomo had faced a revolt from legislators for his handling of nursing-home deaths from COVID. Now, the scandal is acutely personal, with obviously grave political risk.

2 hours ago - Health

Fauci: Children "very likely" to get COVID vaccine at start of 2022

NIAID Director Anthony Fauci. Photo: Win McNamee/Getty Images)

Children under age 12 will "very likely" be able to get vaccinated for coronavirus at the "earliest the end of the year, and very likely the first quarter of 2022," NIAID Director Anthony Fauci told "Meet the Press" Sunday.

Why it matters: Children generally aren't at risk of serious coronavirus infections, but vaccinating them will be key to protecting the adults around them and, eventually, reaching herd immunity, writes Axios' Caitlin Owens.

Virginia lawmakers vote to legalize marijuana in 2024

Virginia Gov. Ralph Northam. Photo: Alex Edelman/Getty Images

Lawmakers in Virginia on Saturday approved compromise legislation that would legalize marijuana in 2024, putting the state a step closer to becoming the first in the South to end prohibition on the drug, the Richmond Times-Dispatch reports.

Why it matters: The legislation will make Virginia the 16th state to legalize marijuana, per Politico. It would add to a slate of laws that have seen Virginia move in a more progressive direction during the tenure of Gov. Ralph Northam.